Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung cancer

Cancer Gene Therapy

Volumn 5, Issue 3, 1998, Pages 183-191

  Joshi, Urwashi S ^a   Chen, Yong Q ^a   Kalemkerian, Gregory P ^a   Adil, Mohmmed R ^a   Kraut, Michael ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Cell growth inhibition; Gene therapy; Lung cancer; p21waf1

Indexed keywords

CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE;

ADENOVIRUS; ANIMAL; ARTICLE; CELL CULTURE; CELL DIVISION; FEMALE; GENE TRANSFER; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MOUSE; MOUSE MUTANT; PATHOLOGY; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032065130     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Parker SL, Tong T, Bolen S, Wingo PA. Cancer Statistics. CA Cancer J Clin. 1997;47(1):5-27.
2. Levin AJ, Momand J. Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products. Biochim Biophys Acta. 1990;1032:119-136.
3. Giaccone G. Oncogenes and antioncogenes in lung tumorigenesis. Chest. 1996;109(5):130S-134S.
4. Greenblatt MS, Harris CC. Molecular genetics of lung cancer. Cancer Surv. 1995;25:293-313.
5. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
6. Gazdar AF, Carbone DP. The Biology and Molecular Genetics of Lung Cancer. Austin, Texas: RG Landes; 1994.
7. Nagatake M, Takagi Y, Oscara H, Uchida K, Mitsudomi T, Saji S, Shimokata K, Takahashi T, Takahashi T. Somatic in vivo alterations of the DPC 4 gene at 18 q 21 in human lung cancers. Cancer Res. 1996;56(12):2718-2720.
8. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, Cordon-Cardo C, Slamon DJ. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer: The lung cancer study group. Oncogene. 1993;8:1913-1919.
9. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC. Mutations and altered expression of genes regulating the cell cycle G1 checkpoint in human cancer. Proc Natl Acad Sci USA. 1994;91:11045-11049.
10. Slebos RJC, Haberts GGM, Evers SG, Mooi WJ, Rodenhuis S. Allele-specific detection of K-ras oncogene expression in human non-small cell lung carcinomas. Int J Cancer. 1991;48:51-56.
11. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-704.
12. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
13. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res. 1994; 211:90-98.
14. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor β includes the cyclin dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA. 1995;92:5545-5549.
15. Zeng YX, El-Deiry WS. Regulation of p21 Waf-1/cip-1 expression by p53-independent pathways. Oncogene. 1996; 12:1557-1564.
16. Chen YQ, Cipriano SC, Sarkar FH, Ware JL, Arenkiel JM. p53-independent induction of p21(WAF1) pathway is preserved during tumor progression. Int J Oncol. 1995;7: 889-893.
17. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816.
18. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 1994;369:574-578.
19. Li CY, Stardet L, Little JB. Potential role of WAF-1/Cip1/ p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem. 1995;270:4971-4974.
20. Zhang H. p21 is a component of active cell kinases. In: Hannon GJ, Casso D, Beach D, eds. Cold Spring Harbor Symposia on Quantitative Biology. New York: Howard Hughes National Institute; 1994;59:21-29.
21. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21 C1P1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 1995;82: 675-684.
22. Brugarolas J, Chandrashekharan C, Gordan JI, Beach D, Jacks T, Hannon GJ. Radiation induced cell cycle arrest compromised by p21 deficiency. Nature. 1995:552-557.
23. Sheikh MS, Rochefort H, Garcia M. Overexpression of p21 WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene. 1995;11:1899-1905.
24. Prabhu NS, Blagosklonny MV, Zeng YX, Wu GS, Waldman T, El-Deiry WS. Suppression of cancer cell growth by adenovirus expressing p21 WAF-1/Cipl deficient in PCNA interaction. Clin Cancer Res. 1996;2:1221-1229.
25. Hung MC, Matin A, Zhang Y, Xing X, Sorgi F, Haung L. HER-2/neu targeting gene therapy: a review. Gene. 1995; 159(1):65-71.
26. Harris MP, Sutjpto S, Wills KN, Hancock W, Cornell D, Johnson DE, Gregory RJ, Shepard HM, Maneval DC. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther. 1996;3(2):121-130.
27. O'Malley BW, Jr, Chen SH, Schwartz MR, Woo SL. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 1995;55(5):1080-1085.
28. Tong XW, Block A, Chen SH, Contant CF, Agfoulnik I, Blankenburg K, Kaufman RH, Woo SL, Kieback DG. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol. 1996;61(2):175-179.
29. Turz T, Cesne AL, Baldeyrou P, Gautier E, Opolon P, Schatz C, Pavirani A, Courtney M, Lamy D, Ragot T, Saulnier P, Andremont A, Monier R, Perricaudet M, Le Chevalier T. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst. 1996;88(24):1857-1863.
30. Xu HJ, Zhou Y, Seigne J, Perng GS, Mixon M, Zang C, Li J, Benedict WF, Hu SX. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated Retinoblastoma protein. Cancer Res. 1996;56:2245-2249.
31. Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Anderson WF, Chiang YL. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 1995;55:5283-5287.
32. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene. 1996;12:1617-1623.
33. Perez-Cruet MJ, Trask TW, Chen SH, Goodman JC, Woo SL, Grossman RG, Shine HD. Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res. 1994; 39(4):506-511.
34. Liu TS, El-Naggar AK, McDonnell TJ, Steck KD, Wang M, Talor DL, Clayman GL. Apoptosis induction mediated by wild type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res. 1995;55(14): 3117-3122.
35. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med. 1995;1(10):1052-1056.
36. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW, Thomson TC. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 1995;55(22): 5151-5155.
37. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst. 1994;86:1458-1462.
38. Zhang Y, Yu D, Xia W, Hung MC. HER-2/neu targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene. 1995;10(10):1947-1954.
39. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KMW, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han C-I, Marin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996;2(9):985-991.
40. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med. 1997;3(3):313-319.
41. Fotedar R, Fitzgerald P, Rousselle T, Cannella D, Doree M, Messier H, Fotedar A. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene. 1996; 12:2155-2164.